Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop and Commercialize MET-X in India

Venus Remedies Ltd., a leading Indian pharmaceutical company, has entered into an exclusive license agreement with Infex Therapeutics, a UK-based anti-infectives specialist. The agreement grants Venus Remedies the rights to develop, register, and commercialize MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, in India. The initial development phase will focus on integrating MET-X with meropenem to tackle drug-resistant Gram-negative bacteria. The agreement also allows both companies to expand their collaboration to include other MBL-inhibitor combinations. MET-X is a broad-spectrum MBL-inhibitor, targeting Gram-negative bacteria that produce MBL enzymes to deactivate beta-lactam antibiotics. The development of new agents to overcome MBL antibiotic resistance is a critical priority for the World Health Organisation.